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A new editorial team for CMI took over in 2008. The ofﬁcial
start of this new team was January 2009; however, for rea-
sons beyond our control, we had to commence before this
date. The organization of the CMI editorial team has changed
so the journal is now led by an Editor-in-Chief (Didier Rao-
ult) with the support of an Associate Editor-in-Chief (Michel
Drancourt) and Associate Editors (Fig. 1) each responsible
for the peer review and revision process of their assigned
manuscripts.
A virologist, Tatjana Avsic Zupano (Ljubljana- Slovenia), will
soon be joining the team, to help manage the increasing
number of submissions the journal is receiving in this area.
The responsibilities of the CMI Scientiﬁc Committee for-
merly titled the Editorial Board are in the process of being
redeﬁned. In the ﬁrst instance, an important contribution
they can make is to act reviewers. This support is very
important at a time when it is becoming a signiﬁcant chal-
lenge to secure agreement from sufﬁcient reviewers.
One of the most important developments for CMI has
been the creation of ‘‘publication’s by theme’’, which seems
to have been a great success (Table 1).
Moreover, the journal’s style and brand has evolved. The
journal has a modern cover design with images that rotate
each issue and reﬂect the theme section. To assist the
reader in navigating the articles in an issue, the table of con-
tents appears on the back cover arranged by theme: bacteri-
ology, virology, infectious diseases and epidemiology.
In terms of the journal’s coverage up until 2007, most of
the articles were related to resistance to antibiotics or phys-
iopathology; however, these two elements have become
minor. Therefore, there has been a very important change
TABLE 1. Theme sections published in CMI in 2009 and
2010
Issue Guest editor Topic
CMI 2009 theme section schedule
January Greub G The medical importance of Chlamydia
February Garau J Resistance: consensus on MRSA
March Cornaglia G Fighting infections due to multidrug-resistant
Gram-positive pathogens
April Paul M Is there a treatment for sepsis other than
antibiotics?
May Cutler SJ Myths, legends and realities of relapsing
fever borreliosis
June Gould E Emerging viruses and the signiﬁcance of
climate change
July Arendrup MC Invasive fungal infections: past achievements
and challenges ahead
August Brouqui P
Ippoito G
Facing highly infectious diseases
September Megraud F Frontiers in Helicobacter research
October Drancourt M Out-of-water: emerging, nontuberculous
mycobacteria
November Pappas G Infectious causes of cancer: an evolving
educational saga
December Reed RC Still difﬁcult; clinical practice guidelines for
Clostridium difﬁcile infection
CMI 2010 theme section schedule
January Cornaglia G
Rossolini GM
The emerging threat of acquired
carbapenemases in Gram-negative bacteria
February Tassios PT
Kerr KG
Hard to swallow
emerging and re-emerging
issues in foodborne infection
March Gautret P Travel medicine, a speciality on the move
April De Lamballerie X Lessons from the HINI inﬂuenza pandemic
in French
overseas territories and interim reports
from metropolitan France
May Mainardi JL
Gutmann L
Streptococcus pneumoniae: still a major
pathogen
June Sundsfjord A
Willems R
Enterococcus research: recent developments
and clinical challenges
July Canton R Cystic ﬁbrosis infection
August Drancourt M Point Of Care : the 21st century
microbiology
September Roilides E
Walsh T
Invasive Fungal Infection in Paediatric
Patients
October Antonelli G Diagnosis issues in the monitoring of HIV
infection
November Greub G MALDI -TOF
December Paul M Cost effectiveness analysis in infectious
diseases
TABLE 2. Original submissions to CMI organized by manu-
script category
Article type 2008 2009 2010 YTD
Correspondence 26 34
Editorial 9 1
Invited editorial 14 12
Invited review 4 54 41
Original article 638 620 570
Research note 206 172 235
Review 25 1
Total 908 896 858
Franz Allerberger,Vienna - Austria
Guido Antonelli, Rome - Italy
Rafael CantÓn, Madrid - Spain
Sally Cutler, London - United Kingdom
Gilbert Greub, Lausanne – Switzerland
Gérard Lina, Lyon - France
Dietrich Mack, Swansea - United Kingdom
Jean-Luc Mainardi, Paris - France
Georgios Pappas, Ioannina - Greece
Mical Paul, Tel Aviv - Israel
Jean-Michel Pawlotsky, Paris - France
Emmanuel Roilides, Thessaloniki - Greece
Panayotis T. Tassios, Athens - Greece
FIG. 1. CMI associate editors and their afﬁliations.
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with CMI presenting more original research on clinical virol-
ogy, mycology, infectious diseases and epidemiology. One of
the future objectives is to publish more articles relating to
parasitology and tropical diseases which are, associated with
travel medicine, because this is becoming a most important
area.
To meet these new challenges, the Scientiﬁc Committee
will be modiﬁed during 2011.
The type of articles submitted to CMI over the past
3 years has evolved (Table 2).
The acceptance rate of original articles has gone from 18%
in 2008 to 27% in 2009 and 23% in 2010 YTD. This is mainly a
consequence of the increased quality of submitted papers.
One important element is that we currently receive many
articles from abroad. The majority of submissions originate
from Europe (63.29%), Asia (19.30%) and then North Amer-
ica (7.15%) (detailed report in Table 3).
Among the articles that have been the most popular, the
10 most cited since the ofﬁcial start of the new team, that is
to say, from the January 2009 issue are shown in Table 4.
Among articles of the theme section, the 10 most quoted
from 2009 are shown in Table 5.
The average citation rate for CMI reviews published in the
ﬁrst 6 months of 2009 is 6.4 compared with an average cita-
tion rate for Lancet infectious disease reviews of 15.3 pub-
lished in the same period (i.e. ﬁrst 6 months of 2009).
In order to have comparable results, we have contrasted
the citation rate of CMI review articles, which on average
are more cited than CMI original articles, with Lancet
Infectious Diseases which is the referential journal for review
articles in this subject area.
For one of CMI’s new elements, we want the journal to
respond to infectious disease events and starting from this
year, the editorial team has requested editorials on ‘‘hot’’
topics such as resistant bacteria in New Delhi, the arrival of
indigenous arboviruses in Europe or the risk of new epidem-
ics of seasonal inﬂuenza. The editorial team is open to
proposals for editorials, either by Associate Editors or even-
tually by scientiﬁc societies to deal with this type of question.
TABLE 3. Manuscripts accepted by country for clinical
microbiology and infection between the January 1st 2008
and October 10th 2010.
Country Accept Reject Total
Accept
ratio %
Albania 0 2 2 0.00
Algeria 0 1 1 0.00
Argentina 4 10 14 28.57
Australia 11 20 31 35.48
Austria 13 13 26 50.00
Bahrain 0 1 1 0.00
Bangladesh 0 2 2 0.00
Belgium 16 23 39 41.03
Bosnia and Herzegovina 0 2 2 0.00
Brazil 10 53 63 15.87
Bulgaria 2 7 9 22.22
Canada 15 17 32 46.88
Chile 0 2 2 0.00
China 17 122 139 12.23
Colombia 2 5 7 28.57
Croatia 0 4 4 0.00
Cuba 0 1 1 0.00
Cyprus 1 1 2 50.00
Czech Republic 1 7 8 12.50
Denmark 20 21 41 48.78
Egypt 0 19 19 0.00
Estonia 0 2 2 0.00
Ethiopia 1 0 1 100.00
Finland 13 14 27 48.15
France 114 130 244 46.72
Germany 28 63 91 30.77
Greece 28 48 76 36.84
Hong Kong 1 7 8 12.50
Hungary 4 5 9 44.44
Iceland 2 2 4 50.00
India 9 88 97 9.28
Iran, Islamic Republic of 2 32 34 5.88
Ireland 7 15 22 31.82
Israel 15 18 33 45.45
Italy 54 83 137 39.42
Jamaica 0 1 1 0.00
Japan 11 40 51 21.57
Jordan 0 4 4 0.00
Kenya 0 1 1 0.00
Korea, Republic of 15 58 73 20.55
Kuwait 0 7 7 0.00
Latvia 0 1 1 0.00
Lebanon 1 9 10 10.00
Libyan Arab Jamahiriya 0 2 2 0.00
Luxembourg 2 0 2 100.00
Malaysia 0 3 3 0.00
Malta 2 0 2 100.00
Mauritius 0 1 1 0.00
Mexico 3 14 17 17.65
Morocco 0 3 3 0.00
Netherlands 39 65 104 37.50
New Caledonia 1 0 1 100.00
New Zealand 1 3 4 25.00
Nigeria 0 4 4 0.00
Norway 12 12 24 50.00
Pakistan 0 12 12 0.00
Palestinian Territory, Occupied 0 2 2 0.00
Peru 0 1 1 0.00
Philippines 1 1 2 50.00
Poland 4 28 32 12.50
Portugal 15 15 30 50.00
Qatar 0 2 2 0.00
Re´union 1 0 1 100.00
Romania 0 4 4 0.00
Russian Federation 2 6 8 25.00
Saudi Arabia 1 10 11 9.09
Senegal 2 1 3 66.67
Serbia 1 7 8 12.50
Singapore 1 6 7 14.29
Slovakia 1 3 4 25.00
Slovenia 1 8 9 11.11
South Africa 1 2 3 33.33
Spain 81 181 262 30.92
Sri Lanka 0 3 3 0.00
Sweden 23 36 59 38.98
Switzerland 30 28 58 51.72
TABLE 3. Continued.
Country Accept Reject Total
Accept
ratio %
Taiwan 27 104 131 20.61
Thailand 5 10 15 33.33
Tunisia 3 11 14 21.43
Turkey 12 77 89 13.48
Ukraine 1 1 2 50.00
United Arab Emirates 0 2 2 0.00
United Kingdom 41 51 92 44.57
United States 48 100 148 32.43
Venezuela 1 2 3 33.33
Total 781 1784 2565 30.45
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These editorials will be free to access and made available
online very rapidly.
In 2010, we were tasked with reducing the backlog of
papers awaiting publication in an issue and thanks to a major
effort by our publisher; we produced four larger issues fea-
turing four times the number of original articles. The size of
these issues inspires a development of this size and quality
and we will see in the future if it is possible to increase the
size of CMI.
Finally, the growth of CMI’s impact factor is satisfac-
tory with the journal achieving a score of above 4 for
the ﬁrst time in the 2009 ISI Journal Citations Report
(Fig. 2).
This is testament to the collective efforts of several Edi-
tor-in-Chief’s who have all participated in the set-up of a
high-quality European journal. It is possible that the 2011
impact factor will be less satisfactory. The impact factor is a
ratio of total citations in a given year to articles published in
the two previous years and the number of articles published
in 2010 will be much higher because of the larger issues pub-
lished to help clear the backlog.
Our goal for 2011 is to have no more than a 4-month
delay between the acceptance of an article and its publication
in a printed issue. From May 2009, accepted unedited CMI
manuscripts have made available online as a PDF within 5
working days. This service provides for the earliest possible
dissemination of research data following article acceptance.
A very signiﬁcant element is the delay for online publication
of accepted articles in several stages; as soon as the article is
accepted by the editor or associate editor, it can be online
within 5 days in its original version and then it is edited at
the publisher, validated by the author, put online to replace
the initial version and it is this version which will be pub-
lished on paper. Therefore, publication times are shortened.
TABLE 4. Most cited articles published in CMI in 2009 and 2010
Author Title Doc type
Times
cited Month Vol(iss)
2009 Articles
Brown et al. The Panton-Valentine leukocidin vaccine protects mice against
lung and skin infections caused by Staphylococcus aureus
USA300
Article 27 February 15(2)
Westh et al. Multiplex real-time PCR and blood culture for identiﬁcation of
bloodstream pathogens in patients with suspected sepsis
Article 19 June 15(6)
Leclercq R Epidemiological and resistance issues in multidrug-resistant
staphylococci and enterococci
Proceedings paper 14 March 15(3)
Donker et al. The population structure of Staphylococcus aureus among
general practice patients from The Netherlands
Article 14 February 15(2)
Greub G Parachlamydia acanthamoebae, an emerging agent of
pneumonia
Review 14 January 15(1)
Kopterides and Falagas Statins for sepsis: a critical and updated review Review 11 April 15(4)
Cornaglia and Rossolini Forthcoming therapeutic perspectives for infections due to
multidrug-resistant Gram-positive pathogens
Proceedings Paper 11 March 15(3)
Croze et al. Serum antibodies against Panton-Valentine leukocidin in a
normal population and during Staphylococcus aureus
infection
Article 10 February 15(2)
Marconi et al. Evaluation of the Abbott Real-Time HIV-1 quantitative assay
with dried blood spot specimens
Article 10 January 15(1)
Worlitzsch et al. Antibiotic-resistant obligate anaerobes during exacerbations of
cystic ﬁbrosis patients
Article 9 May 15(5)
2010 Articles
Miriagou et al. Acquired carbapenemases in Gram-negative bacterial
pathogens: detection and surveillance issues
Proceedings Paper 6 February 16(2)
Allerberger F; Wagner M Listeriosis: a resurgent foodborne infection Review 5 January 16(1)
Teo CG Much meat, much malady: changing perceptions of the
epidemiology of hepatitis E
Review 4 January 16(1)
Castagnola et al. Performance of the galactomannan antigen detection test in
the diagnosis of invasive aspergillosis in children with cancer
or undergoing haemopoietic stem cell transplantation
Article 3 August 16(8)
Wallet et al. Preliminary clinical study using a multiplex real-time PCR test
for the detection of bacterial and fungal DNA directly in
blood
Article 3 June 16(6)
Utzinger et al. Microscopic diagnosis of sodium acetate-acetic acid-formalin-
ﬁxed stool samples for helminths and intestinal protozoa: a
comparison among European reference laboratories
Article 3 March 16(3)
Cornaglia, G; Rossolini, GM The emerging threat of acquired carbapenemases in Gram-
negative bacteria
Editorial Material 3 February 16(2)
Carmeli et al. Controlling the spread of carbapenemase-producing Gram-
negatives: therapeutic approach and infection control
Proceedings Paper 3 February 16(2)
Weese, JS Clostridium difﬁcile in food-innocent bystander or serious
threat?
Review 3 January 16(1)
Dupont et al. Identiﬁcation of clinical coagulase-negative staphylococci,
isolated in microbiology laboratories, by matrix-assisted laser
desorption/ionization-time of ﬂight mass spectrometry and
two automated systems
Article 2 July 16(7)
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The current (2010 YTD) delay of ﬁnal acceptance of arti-
cles is of 69 days, 10 days for immediate rejection, 26 days
for acceptance, revision or rejection after peer review (i.e.
time to ﬁrst decision).
These turnaround times appear reasonable when com-
pared to CMI’s competitors although we will strive to better
these in the future.
The objective of the journal is to give a rapid response in
cases where a manuscript is immediately rejected and a
response of reasonable substance in cases of refusal after
peer review.
Transparency Declaration
There is no conﬂict to declare.
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FIG. 2. Indicates the kinetics of the evolution of the impact factor
over 8 years with arrows indicating the term of ofﬁce of the past
and present CMI Editor-in-Chiefs.
TABLE 5. Most cited CMI thematic reviews
Rank Author Title
Times
cited
1 Leclercq R Epidemiological and resistance issues in
multidrug-resistant staphylococci and
enterococci
15
2 Greub G Parachlamydia acanthamoebae, an emerging
agent of pneumonia
14
3 Cornaglia G,
Rossolini GM
Forthcoming therapeutic perspectives for
infections due to multidrug-resistant Gram-
positive pathogens
12
4 Kopterides P,
Falagas ME
Statins for sepsis: a critical and updated
review
11
5 Struelens et al. Laboratory tools and strategies for methicil
lin-resistant Staphylococcus aureus
screening, surveillance and typing: state of
the art and unmet needs
9
6 Blasi et al. Chlamydophila pneumoniae 8
7 Lode HM Clinical impact of antibiotic-resistant Gram-
positive pathogens
8
8 Be´be´ar C, de
Barbeyrac B
Genital Chlamydia trachomatis infections 7
9 Kern et al. Molecular pathogenesis of chronic
Chlamydia pneumoniae infection: a brief
overview
7
10 Erjavec et al. Trends in invasive fungal infections, with
emphasis on invasive aspergillosis
6
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